肾癌组织中P-gp、TopoⅡ、GST-π及ki67、p53表达的临床病理意义

Co-expression of P-gp, TopoⅡ, GST-π and ki67, p53 Protein in Renal Carcinoma

目的 探讨肾癌组织中 P-糖蛋白 (P- gp)、拓扑异构酶 (Topo )、谷胱甘肽 - S-转移酶 (GST- π)和 ki6 7、p5 3表达与其生物学行为及预后的关系。 方法 用免疫组织化学方法检测 6 0例术前未进行化疗的肾癌组织中P170、Topo 、GST-π和 ki6 7、p5 3的表达。 结果 P- gp表达与组织学类型、组织学分级无关 ,与临床分期相关 (P<0 .0 5 ) ;Topo 表达与分型、分期无关 ,与分级明显相关 (P<0 .0 1)。 ki6 7表达与分级、分期密切相关 (P<0 .0 1) ,与组织学类型无关 ;GST- π和 p5 3均与分型、分级、分期无关。 结论 应用免疫组织化学法检测肾癌组织中 P- gp、Topo 、GST- π和 ki6 7、p5 3的表达 。

Objective\ To explore the correlation of co\|expression of P\|glycoprotein(P\|gp), glutathione\|s\|transferase\|π(GST\|π), topoisomeraseⅡ(TopoⅡ) and ki67, p53 protein with biological behaviors and prognosis of renal carcinoma.\ Methods\ sixty patients with renal carcinoma, never start chemotherapy before surgery, were studied for expression of P\|gp, TopoⅡ, GST\|π, ki67 and p53 protein in the tumor tissue with immunohistochemistry.\ Results\ The expression of P\|gp not correlated with histology type and cel...